Advertisement

Hypophysenvorderlappen und Austestung der glandotropen Achsen

  • Andreas Schäffler
  • Cornelius Bollheimer
  • Roland Büttner
  • Christiane Girlich
  • Charalampos Aslanidis
  • Wolfgang Dietmaier
  • Margarita Bala
  • Viktoria Guralnik
  • Thomas Karrasch
  • Sylvia Schneider
Chapter

Zusammenfassung

Erläutert werden alle relevanten Funktionstests mit ausführlicher Darstellung von Indikationen, Kontraindikationen, Nebenwirkungen, Testvorbereitung, Rahmenbedingungen, konkreten Handlungsanleitung der eigentlichen Testdurchführung sowie der Interpretation der Testergebnisse. Es werden immer konkrete Normbereiche und Cut-off-Werte angegeben, auch für besondere Situationen (Geschlecht, Alter, BMI, Pubertätsphasen, Zyklusphasen, akute Erkrankungen, Medikamente etc.). Ein besonderes Merkmal ist die Betonung der Testvorbereitung, -durchführung und -interpretation sowie des interdisziplinären Charakters. Die Hypophysenvorderlappen-Hormone und ihre dynamische Funktionstestung werden in diesem Kapitel detailliert behandelt. Auch schwierige, aufwändige und seltene Testverfahren wie Sinus-petrosus-inferior-Katheterisierung, pulsatiler GnRH-Test und kombinierter GHRH-Arginin-Infusions-Test sind ausführlich dargestellt.

Literatur

  1. 1.
    Thomas L (2008) Labor und Diagnose, 7. Aufl. TH-Books Verlagsgesellschaft, Frankfurt, S 1444–1445, 1780Google Scholar
  2. 2.
    Lehnert H, Allolio B, Buhr HJ, Hahn K, Mann B, Mohnike K, Weiss M (2003) Nebenniere. In: Lehner H (Hrsg) Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Thieme, Stuttgart, S 22–23Google Scholar
  3. 3.
    Quabbe HJ, Müller OA, Oelkers W, Willig RP (1993) Hypothalamus und Hypophyse. In: Deutsche Gesellschaft für Endokrinologie (Hrsg) Rationelle Diagnostik in der Endokrinologie. Thieme, Stuttgart/New York, S 30Google Scholar
  4. 4.
    Murphy BE (1967) Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay. J Clin Endocrinol Metab 27:973–990CrossRefPubMedGoogle Scholar
  5. 5.
    Cooper MS (2003) Corticosteroid insufficiency in acutely ill patients. NEJM 348:727–734CrossRefPubMedGoogle Scholar
  6. 6.
    Van Rijn JL, Van Landeghem BA, Haima P, Goldschmidt HM (1996) Evaluation of ACTH immunoradiometric assays. Clin Biochem 29:93–95CrossRefPubMedGoogle Scholar
  7. 7.
    Findling JW, Raff H (2006) Cushing’s syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91:3746–3753CrossRefPubMedGoogle Scholar
  8. 8.
    Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GB Jr, Loriaux DL (1991) Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 325:897–905CrossRefPubMedGoogle Scholar
  9. 9.
    Raff H, Findling JW (2003) A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 138:980–991CrossRefPubMedGoogle Scholar
  10. 10.
    Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practive guideline. JCEM 101:3888–3921PubMedPubMedCentralGoogle Scholar
  11. 11.
    Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, Monson JP, Grossman AB, Besser GM, Trainer PJ (1999) A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing’s disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84:487–492PubMedGoogle Scholar
  12. 12.
    Grua JR, Nelson DH (1991) ACTH-producing pituitary tumors. Endocrinol Metab Clin North Am 20:319–362PubMedGoogle Scholar
  13. 13.
    Fiad TM, Kirby JM, Cunningham SK, McKenna TJ (1994) The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 40:603–609CrossRefGoogle Scholar
  14. 14.
    Avgerinos PC, Yanovski JA, Oldfield EH, Nieman LK, Cutler GB Jr (1994) The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med 121:318–327CrossRefPubMedGoogle Scholar
  15. 15.
    Tirabassi G et al (2010) Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J Clin Endocrinol Metab 95:1115–1122CrossRefPubMedGoogle Scholar
  16. 16.
    Vassiliadi DA et al (2016) The Desmopressin Test Predicts Better Than Basal Cortisol the Long-Term Surgical Outcome of Cushing’s Disease. J Clin Endocrinol Metab 101:4878–4885CrossRefPubMedGoogle Scholar
  17. 17.
    Colombo P et al (1997) Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess. Clin Endocrinol (Oxf) 46:661–668CrossRefGoogle Scholar
  18. 18.
    Tirabassi G et al (2011) Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing’s disease and pseudo-Cushing state: a comparative study. Clin Endocrinol (Oxf) 75:666–672CrossRefGoogle Scholar
  19. 19.
    Wang HF, Huang CC, Chen YF, Ho DM, Lin HD (2007) Pituitary apoplexy after thyrotropin-releasing hormone stimulation test in a patient with pituitary macroadenoma. J Chin Med Assoc 70:392–395CrossRefGoogle Scholar
  20. 20.
    Thomas L (2008) Labor und Diagnose, 7. Aufl. TH-Books Verlagsgesellschaft, Frankfurt, S 1387Google Scholar
  21. 21.
    Partsch CJ, Hummelink R, Sippell WG (1990) Reference ranges of lutropin and follitropin in the luliberin test in prepubertal and pubertal children using a monoclonal immunoradiometric assay. J Clin Chem Clin Biochem 28:49–52PubMedGoogle Scholar
  22. 22.
    Wiedemann G, Jonetz-Mentzel L, Panse R (1993) Establishment of reference ranges for follitropin and lutropin in neonates, infants, children and adolescents. Eur J Clin Chem Clin Biochem 31:395–401PubMedGoogle Scholar
  23. 23.
    Larsen PR, Kronenberg HM, Melme S, Polonsky KS (Hrsg) (2003) Williams textbook of endocrinology. Saunders/Elsevier, PhiladelphiaGoogle Scholar
  24. 24.
    Leidenberger F (1998) Klinische Endokrinologie für Frauenärzte. Springer, BerlinCrossRefGoogle Scholar
  25. 25.
    Smals AG, Hermus AR, Boers GH, Pieters GF, Benraad TJ, Kloppenborg PW (1994) Predictive value of luteinizing hormone releasing hormone (LHRH) bolus testing before and after 36-hour pulsatile LHRH administration in the differential diagnosis of constitutional delay of puberty and male hypogonadotropic hypogonadism. J Clin Endocrinol Metab 78:602–608PubMedGoogle Scholar
  26. 26.
    Partsch CJ, Sippell WG (1987) Short-term pulsatile administration of luteinizing hormone releasing hormone in male adolescents with multiple idiopathic pituitary hormone deficiencies. Horm Res 25:88–96CrossRefPubMedGoogle Scholar
  27. 27.
    Elmlinger MW, Kuhnel W, Weber MM, Ranke MB (2004) Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654–664CrossRefPubMedGoogle Scholar
  28. 28.
    Thomas L (2008) Labor und Diagnose, 7. Aufl. TH-Books Verlagsgesellschaft, Frankfurt, S 1463Google Scholar
  29. 29.
    Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M (2005) Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 152:165–170CrossRefPubMedGoogle Scholar
  30. 30.
    Ranke MB (1993) Endokrinologische Funktionsdiagnostik im Kindes- und Jugendalter. J & J Verlag, MannheimGoogle Scholar
  31. 31.
    Thalange NK, Price DA, Gill MS, Whatmore AJ, Addison GM, Clayton PE (1996) Insulin-like growth factor binding protein-3 generation: an index of growth hormone insensitivity. Pediatr Res 39:849–855CrossRefPubMedGoogle Scholar
  32. 32.
    Blum WF, Ranke MB, Savage MO, Hall K (1992) Insulin-like growth factors and their binding proteins in patients with growth hormone receptor deficiency: suggestions for new diagnostic criteria. The Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatr Suppl 383:125–126PubMedGoogle Scholar
  33. 33.
    Engstrom BE, Karlsson FA, Wide L (1998) Marked gender differences in ambulatory morning growth hormone values in young adults. Clin Chem 44:1289–1295PubMedGoogle Scholar
  34. 34.
    Soldin SJ, Brugnara C, Wong EC (Hrsg) (2003) Pediatric reference ranges. AACC Press, Washington, DC, S 104–105Google Scholar
  35. 35.
    Ranke MB, Gruhler M, Rosskamp R, Brugmann G, Attanasio A, Blum WF, Bierich JR (1986) Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency. Eur J Pediatr 145:485–492CrossRefPubMedGoogle Scholar
  36. 36.
    Audi L, Granada ML, Carrascosa A (1996) Growth hormone secretion assessment in the diagnosis of short stature. J Pediatr Endocrinol Metab 9(Suppl 3):313–324PubMedGoogle Scholar
  37. 37.
    Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG, Grottoli S, Maccario M, Colao A, Lombardi G, Ghigo E, Camanni F, Aimaretti G (2005) The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153:257–264CrossRefPubMedGoogle Scholar
  38. 38.
    Saini S, Hindmarsh PC, Matthews DR, Pringle PJ, Jones J, Preece MA, Brook CG (1991) Reproducibility of 24-hour serum growth hormone profiles in man. Clin Endocrinol (Oxf) 34:455–462CrossRefGoogle Scholar
  39. 39.
    Tassoni P, Cacciari E, Cau M, Colli C, Tosi M, Zucchini S, Cicognani A, Pirazzoli P, Salardi S, Balsamo A et al (1990) Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. J Clin Endocrinol Metab 71:230–234CrossRefGoogle Scholar
  40. 40.
    Corneli G, Di Somma C, Prodam F, Bellone J, Bellone S, Gasco V, Baldelli R, Rovere S, Schneider HJ, Gargantini L, Gastaldi R, Ghizzoni L, Valle D, Salerno M, Colao A, Bona G, Ghigo E, Maghnie M, Aimaretti G (2007) Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol 157:701–708CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ranke MB, Wallaschofski H (2009) Considerations of growth hormone treatment during the transition from adolescence to adulthood. Dtsch Med Wochenschr 134:1117–1120CrossRefPubMedGoogle Scholar
  42. 42.
    Ho KK (2007) Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695–700CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hauffa BP (2014) Wachstumshormontherapie in der Transitionsphase. Endokrinologie-Informationen der DGE, Sonderheft, S 9Google Scholar
  44. 44.
    Molitch ME et al (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587–1609CrossRefPubMedGoogle Scholar
  45. 45.
    Berg C et al (2010) Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol 162:477–482CrossRefPubMedGoogle Scholar
  46. 46.
    Fleseriu M et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888–3921CrossRefPubMedGoogle Scholar
  47. 47.
    Hamrahian AH et al (2016) Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. Pituitary 19:332–341CrossRefPubMedGoogle Scholar
  48. 48.
    Yuen KC et al (2016) American association of clinical endocrinologists and American college of endocrinology disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 22:1235–1244Google Scholar
  49. 49.
    Kavanagh L, McKenna TJ, Fahie-Wilson MN, Gibney J, Smith TP (2006) Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem 52:1366–1372CrossRefPubMedGoogle Scholar
  50. 50.
    Sanchez-Eixeres MR, Mauri M, Alfayate R, Graells ML, Miralles C, Lopez A, Pico A (2001) Prevalence of macroprolactin detected by Elecsys 2010. Horm Res 56:87–92PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2018

Authors and Affiliations

  • Andreas Schäffler
    • 1
  • Cornelius Bollheimer
    • 2
  • Roland Büttner
    • 3
  • Christiane Girlich
    • 4
  • Charalampos Aslanidis
    • 5
  • Wolfgang Dietmaier
    • 6
  • Margarita Bala
    • 7
  • Viktoria Guralnik
    • 8
  • Thomas Karrasch
    • 1
  • Sylvia Schneider
    • 9
  1. 1.Klinik und Poliklinik für Innere Medizin IIIUniversitätsklinikum Gießen und Marburg (UKGM), Standort GiessenGiessenDeutschland
  2. 2.Lehrstuhl für Geriatrie, Universitätsklinikum AachenUniversität AachenAachenDeutschland
  3. 3.Abteilung für Innere MedizinCaritas Krankenhaus St. Josef, RegensburgRegensburgDeutschland
  4. 4.Klinik für Allgemeine Innere Medizin und GeriatrieKrankenhaus der Barmherzigen BrüderRegensburgDeutschland
  5. 5.Institut für Klinische Chemie und LaboratoriumsmedizinKlinikum der Universität RegensburgRegensburgDeutschland
  6. 6.Institut für PathologieKlinikum der Universität RegensburgRegensburgDeutschland
  7. 7.Medizinische Klinik und Poliklinik IUniversitätsklinikum WürzburgWürzburgDeutschland
  8. 8.Abteilung für Innere MedizinKlinikum BogenBogenDeutschland
  9. 9.Klinik und Poliklinik für Innere Medizin IKlinikum der Universität RegensburgRegensburgDeutschland

Personalised recommendations